• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . The hyaluronan receptor CD44 drives COVID-19 severity through its regulation of neutrophil migration

tetano

Editor, Senior Moderator
PLoS Pathog


. 2026 May 20;22(5):e1013619.
doi: 10.1371/journal.ppat.1013619. Online ahead of print.
The hyaluronan receptor CD44 drives COVID-19 severity through its regulation of neutrophil migration

Duncan J Hart[SUP] 1 [/SUP], Md Jashim Uddin[SUP] 1 [/SUP], Rebecca J Dodd[SUP] 2 3 [/SUP], Savannah G Brovero[SUP] 1 [/SUP], Claire Fleming[SUP] 1 [/SUP], G Brett Moreau[SUP] 4 5 [/SUP], Nick R Natale[SUP] 6 [/SUP], Farha Naz[SUP] 4 [/SUP], Barbara J Mann[SUP] 1 4 [/SUP], Tara E Sutherland[SUP] 7 [/SUP], Judith E Allen[SUP] 2 3 [/SUP], Anthony J Day[SUP] 2 3 [/SUP], William A Petri Jr[SUP] 1 4 8 [/SUP]


Affiliations
Abstract

The novel respiratory disease COVID-19 caused by the coronavirus SARS-CoV-2 continues to be a public health emergency worldwide, and there is a need for more effective therapy for patients. The relationship between the extracellular matrix and the host immune response to infection is severely understudied. Deposition of the polysaccharide hyaluronan (HA) into the lungs is associated with more severe COVID-19 disease outcomes. HA is a major component of the extracellular matrix in connective tissues and is abundant in many parts of the body, including cartilage, skin, brain, and vitreous body. HA is a major component of the extracellular matrix in connective tissues and is abundant in many parts of the body, including cartilage, skin, brain, and vitreous body. Polymers consist of repeating units of N-acetylglucosamine and glucuronic acid and are synthesized by the three hyaluronan synthase (HAS) enzymes, HAS1-3. CD44 is the primary receptor for HA and is found on almost all immune cells in the lung. Known functions of CD44 include mediation of immune cell migration, activation, and differentiation. We hypothesized that increased HA deposition during COVID-19 increases CD44-mediated immune cell infiltration into lungs and results in more severe pathology. Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection. We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4. With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs. We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HA's interaction with immune cells contributes to pathology. Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.


 
Back
Top